New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social @israelsenm.bsky.social

How should we use PEth in SLD care? 🩸🍺 Our study in @lancetgastrohep.bsky.social (n≈3,000) shows: 🔍 39% of MASLD → MetALD/ALD with PEth ⨻ Triangulating self-report + AUDIT-C + PEth = better classification ⚖️ But 40% get no added value → use selectively www.sciencedirect.com/science/arti...

New Review - Screening for advanced steatotic liver disease www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social

🎉Our new Impact Factor is 7.5! We are firmly among the top journals in hepatology👏 Thank you to our authors, reviewers & readers!🙏 #LiverSky @easlnews.bsky.social

New Editorial — Alcohol and health: time for Europe to sober up www.thelancet.com/journals/lan... #alcohol #liversky #medsky

📢Our new Impact Factor is 33.0🎉 🥇Ranking number 1 in the Hepatology field🥇 👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕ #LiverSky @easlnews.bsky.social

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement. 🗓️ What a fun #workshop at #EASLCongress 2025

🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators. 📅 Presented at the #EASLCongress | #EASL2025

One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋 As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona. Thank you for an inspiring #EASLCongress - see you next year!

🤩 Full house at General Session 1 today 🥳 Abstract Session “General #Hepatology”, chaired by Aleksander Krag from Odense University Hospital in Denmark 🇩🇰, featuring a broad range of cutting-edge #LiverResearch 🔬. 📅 Presented at #EASLCongress | #EASL2025 🕥 10:30 – 12:30 h @easlnews.bsky.social

📚 Learning from the best at the EASL Congress: Maja Thiele (OUH) discusses Alcohol-related liver disease as part of The JHEP Reports Symposium: Keys to get your manuscript accepted. 💡 #EASL2025

🐭 Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease #POSTER THU-058-YI by Maximilian Brol (UM) presents preclinical data showing that blocking MFAP4 reduces #liver #fibrosis in two murine models. #EASL2025

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM #MedSky #EndoSky #GastroSky

🚨New paper from us in Journal of Hepatology - Using PEth values on >50,000 persons to predict outcomes. www.sciencedirect.com/science/arti...

APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol" www.nature.com/articles/s41... #Liversky

@aga-cgh.bsky.social @majathiele.bsky.social @aleksanderkrag.bsky.social #Thorhauge

Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️ Over 60% with MetALD/ALD and 38% with MASLD change subclass. This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐 Link: www.cghjournal.org/article/S154...

#liversky #gastrosky #oncsky

MASLD vs MetALD/ALD is often reduced to ‘alcohol or not’. But alcohol use is not binary—and SLD is a dynamic spectrum where alcohol plays a significant role across phenotypes. Time to rethink the simplistic divide 🧐 @aleksanderkrag.bsky.social @natrevgastrohep.bsky.social

Have you secured your spot for #EASLCongress 2025 on 7-10 May? 🌍Join us in Amsterdam or online to transform liver care worldwide! easlcongress.eu/2025-registr... 📜The deadline to submit your late-breaker abstract is TODAY, 17 March! easlcongress.eu/2025-abstrac...

New Review - Neurath, Artis, Becker - The intestinal barrier: a pivotal role in health, inflammation, and cancer www.thelancet.com/journals/lan... #GastroSky #MedSky

AASLD is here @aasldnews.bsky.social @aasldfoundation.bsky.social #liversky

We're once again hosting the Human #Microbiome conference at @embl.org, organized by Ami Bhatt, Nicola Segata, Mani Arumugam and Peer Bork! We always have a great lineup of speakers, so register now and think about an abstract to submit (abstract submission deadline in June)

Journal of Hepatology is now on Bluesky 🌤️ 📢Check our January issue❗️ 🎉Celebrating 40 years of discovery in #liverresearch🎉 🙏Thank you to our authors, editors, reviewers, & readers for supporting us on this incredible journey Full issue here👉https://bit.ly/42en2Kp #LiverSky @easlnews.bsky.social

🚀 Join #EASLCongress 2025 (7–10 May, Amsterdam & online) for cutting-edge hepatology, expert insights & hands-on training! Register Now 👉 easlcongress.eu/2025-registr... Scientific Programme 👉https://www.easlcongress.eu/2025-scientific-programme/

🚀 7th GA #Meeting in Cologne, Germany from 27-29 January 2025! A huge thank you to everyone for sharing their latest results and project updates! 👏 And of course, we wrapped it up with some after-work fun, exploring Cologne with a @sciencerallye.bsky.social! 🏙️ ⛲

Happy to share a new review article in JHep Reports written by @mattiasmandorfer.bsky.social @juanabraldes.bsky.social and myself - take a look! www.jhep-reports.eu/article/S258...

JHEP Reports has published our update cirrhosis epidemiology in Denmark: www.sciencedirect.com/science/arti... Our population of cirrhosis patients is changing: They're older now than they used to be, and fewer have ALD. The incidence of ALD is decreasing in Denmark, unlike in so many other places.

Feeling butterflies in your tummy? 🦋 It’s not just Valentine’s Day - it’s the excitement of MICROB-PREDICT joining #Bluesky! 🙌 Let’s connect! 🌐 @easlnews.bsky.social @decision4liver.bsky.social @amelischwalber.bsky.social @concentris.bsky.social @a-tango.bsky.social @ninadonner.bsky.social

BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis Congratulations to Elisa Pose And congrats to @jama.com for getting this paper #liversky t.co/BuPL0mURhl

The Lancet Gastroenterology & Hepatology is now on Bluesky! bsky.app/profile/lanc... Follow us! #GastroSky #LiverSky #MedSky

#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.! easl.eu/easl-studio-...

The authors of today’s #readoftheweek📚 discuss the functional genetic study of protein-altering variants, and how it provides insights on the association between loss of TM6SF2 function and #SLD. Read here this JHEP Reports article: www.jhep-reports.eu/article/S258... #LiverSky

We tend to think that all decompensated cirrhosis are the same. During the 12 years that I practiced in the USA, I learnt that MASLD cirrhosis is different. See below the 10 more common specific medical issues of MASLD CIRRHOSIS that I found:

AlbTrial Update 🏥 70 out of 240 included But what is AlbTrial? AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis. 🔗 bmjopen.bmj.com/content/bmjo... 🧵below Annual General Assembly in MicrobPredict #liversky #cirrhosis

@suguru-nishijima.bsky.social @borklab.bsky.social @biocs.bsky.social @evelinastn.bsky.social @majathiele.bsky.social @aleksanderkrag.bsky.social

Efruxifermin reversing some cirrhosis in phase 2b ir.akerotx.com/news-release...

There has been a recent influx to #gisky and #liversky To sustain this, you need to be active. If you were a lurker, no we need your pearls, papers, and pets. Post. Use the hashtags. Build.

What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease? @aleksanderkrag.bsky.social and colleagues discuss… www.thelancet.com/journals/lan... #GastroSky #MedSky

Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit Huge attendance and interest! 👏🏼 @tom-marjot.bsky.social @madsisraelsen.bsky.social